| Study Period | 2019 - 2030 |
| 乐鱼体育官网 Size (2025) | USD 1.17 Billion |
| 乐鱼体育官网 Size (2030) | USD 2.51 Billion |
| CAGR (2025 - 2030) | 16.60 % |
| Fastest Growing 乐鱼体育官网 | Asia Pacific |
| Largest 乐鱼体育官网 | North America |
| 乐鱼体育官网 Concentration | High |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Monoclonal Antibodies In Veterinary Health 乐鱼体育官网 Analysis
The Monoclonal Antibodies In Veterinary Health 乐鱼体育官网 size is estimated at USD 1.17 billion in 2025, and is expected to reach USD 2.51 billion by 2030, at a CAGR of 16.6% during the forecast period (2025-2030).
The monoclonal antibodies in veterinary health 乐鱼体育官网 is strengthened by various factors, such as the rising burden of chronic disorders among animals, the high adoption rate of pets and concerns for pet care, and growing investments for significant therapeutic monoclonal antibodies.
The increased burden of chronic disorders and infections, including atopic dermatitis, cancer, diabetes, and autoimmune diseases among animals, leads to the high demand for monoclonal antibodies to treat and prevent disorders, boosting 乐鱼体育官网 growth. For instance, the article published in the Journal of Veterinary Sciences in November 2023 provided data that canine atopic dermatitis (CAD) is a common and troublesome chronic allergic skin condition that impacts around 20% to 30% of dogs. Similarly, the Veterinary Cancer Society in 2023 reported that cancer is contributing significantly to the deaths of 47% of dogs and 32% of cats. Thus, the high burden of chronic disorders among animals is expected to raise the demand for monoclonal antibodies in their treatments, propelling 乐鱼体育官网 growth over the forecast period.
Pet owners are increasing yearly, coupled with growing concerns about maintaining pet healthcare and services. The increase in the number of pet owners would lead to the growth in the 乐鱼体育官网 of monoclonal antibodies in veterinary health. For instance, as per the 2023-2024 report issued by the American Pet Products Association (APPA), 70% of American households adopted a pet, accounting for 90.5 million households. According to the North American Pet Health Insurance Association (NAPHIA), in 2023, the number of insured pet animals increased by 20.9% from 2022 (around 5.17 million pets), accounting for 6.25 million. The significant growth in expenditures due to the rising concerns for therapies and treatments is driving 乐鱼体育官网 growth.
Furthermore, the 乐鱼体育官网 players are focusing on introducing new monoclonal antibodies for animals to improve their health, contributing to 乐鱼体育官网 growth. For instance, in June 2023, Zoetis introduced the first monoclonal antibody, Oclactinib tablet (Apoquel), for treating atopic dermatitis in dogs. It provided data demonstrating the clinical efficacy and tolerating response with positive results. In May 2023, Elanco introduced the first and only approved monoclonal antibody product, which effectively treats canine parvovirus, ensuring clinical safety and effectiveness with a single dosage in dogs. Thus, to control the high impact of diseases among animals, there is a need to adopt measures and treatments that contribute to the 乐鱼体育官网 growth of monoclonal antibodies.
Thus, the rising number of chronic disorders and infections among animals and pet owners' growing interest and concerns associated with animal health maintenance are expected to contribute significantly to 乐鱼体育官网 growth. However, the high costs of animal healthcare products and treatments and stringent regulatory issues are the main factors expected to hinder 乐鱼体育官网 growth during the forecast period.
Monoclonal Antibodies In Veterinary Health 乐鱼体育官网 Trends
The Dogs Segment is Witnessed to Hold the Highest 乐鱼体育官网 Share During the Forecast Period
The dogs segment holds the most significant portion of the 乐鱼体育官网 due to the increase in the number of dog pet owners and associated healthcare expenditures. Furthermore, the accessibility of many monoclonal antibody products for dogs fuels 乐鱼体育官网 growth. For instance, the data published by the Shelter Animals Count (SAC) Organization in December 2023 mentioned an increase of 109,000 dog adoptions in 2023 compared to 2022. Thus, the increase in dog adoption is expected to boost the demand for monoclonal antibodies for dogs and boost 乐鱼体育官网 growth.
Moreover, the increase in concerns about healthcare treatments and the adoption of pet insurance raises 乐鱼体育官网 growth. The increased population growth of dogs can be associated with high healthcare expenditures and the insurance adoption rate for dogs compared to other animals. For instance, according to the data published by the North American Pet Health Insurance Association (NAPHIA) in May 2023, dogs accounted for the largest share of insured pets, representing 80.1% of all insured animals, while insured cats accounted for only 19.9% in the United States. Pet owners seek the latest treatments to care for their animals, such as monoclonal antibodies, which contribute to the segment鈥檚 growth.
Additionally, 乐鱼体育官网 players employ strategies such as product launches to increase the accessibility and availability of different monoclonal antibodies for dogs, thus boosting 乐鱼体育官网 growth. For instance, in May 2023, Elanco introduced the first monoclonal antibody for treating canine parvovirus among dogs. In May 2023, Zoetis received approval from the US Food and Administration (FDA) for Librela monoclonal antibody in the management of osteoarthritis pain. Thus, such 乐鱼体育官网 player initiatives are anticipated to drive the segment鈥檚 growth.
Therefore, the dogs segment is expected to record the highest share in the 乐鱼体育官网 due to the growing number of pet owners adopting dogs and the availability of significant therapies for maintaining pet health.
Understand The Key Trends Shaping This 乐鱼体育官网
Download PDF
North America is Expected to Hold the Largest 乐鱼体育官网 Share in the Monoclonal Antibodies in Veterinary Health 乐鱼体育官网
North America is expected to hold the largest part of the 乐鱼体育官网 share. This is attributed to significant factors such as support and initiatives provided by the government and other animal healthcare organizations and rising pet insurance.
There has been an increase in the number of pet insurers and manufacturing companies developing monoclonal antibody-based treatments. For instance, data published by the North American Pet Health Insurance Association (NAPHIA) in April 2024 mentioned that the North American pet insurance 乐鱼体育官网 reached USD 4.27 billion in premiums sold in 2023, marking a 21.9% increase from the USD 3.5 billion reported in 2022. Additionally, NAPHIA highlighted that with an estimated total of more than 170.4 million pets in North America, the average penetration rates are 3.69% in the United States and 3.52% in Canada. Thus, the increasing adoption of pet insurance is anticipated to drive the demand for monoclonal antibodies for animals and contribute to 乐鱼体育官网 growth in the region.
Moreover, the rising pet healthcare expenditures are anticipated to boost the adoption of monoclonal antibody treatment for animals and drive 乐鱼体育官网 growth. For instance, data from the American Pet Products Association (APPA) in August 2024 reported that veterinary care, with huge expenditures comprising pharmaceuticals obtained through veterinary hospitals, accounted for USD 150.6 billion (estimated) in 2024 compared to 147.0 billion in 2023, thus fueling 乐鱼体育官网 growth.
Moreover, growing investments, research, and product approvals are fueling 乐鱼体育官网 growth. For instance, in July 2023, Invetx introduced the completion of its species-specific half-life extension technology for dogs and cats. The innovative technology empowers the company to improve treatment options for chronic and severe diseases in canine and feline patients with an enhanced duration of activity for the veterinary monoclonal antibodies. Additionally, the company has been awarded four patents in the United States pertaining to its half-life extension technology. In May 2023, Zoetis received the US Food and Drug Administration approval for the first monoclonal antibody - Librela (bedinvetmab injection), which can be used for pain management caused by osteoarthritis in dogs and cats.
Thus, high expenditures by pet owners and advancement in the research and development of new drugs and therapies involving monoclonal antibodies are expected to lead to 乐鱼体育官网 growth over the forecast period.
Get Analysis on Important Geographic 乐鱼体育官网s
Download PDF
Monoclonal Antibodies In Veterinary Health Industry Overview
The 乐鱼体育官网 for monoclonal antibodies in veterinary health is highly consolidated due to the high competitiveness and limited number of players. Major key players are comprised of Zoetis, Merck & Co., Elanco, Boehringer Ingelheim Gmbh, Indian Immunologicals Ltd, Virbac, Bayer Animal Health, Invetx, Advio Gmbh, and Kindred Biosciences. The companies are incorporating various approaches and strategies involving product launches, collaborations, and increased technological investments to broaden the product portfolio and expand geographically.
Monoclonal Antibodies In Veterinary Health 乐鱼体育官网 Leaders
-
Merck & Co
-
Bayer Animal Health
-
Zoetis
-
Elanco
-
Boehringer Ingelheim Gmbh
- *Disclaimer: Major Players sorted in no particular order
Need More Details on 乐鱼体育官网 Players and Competiters?
Download PDF
Monoclonal Antibodies In Veterinary Health 乐鱼体育官网 News
- August 2024: Elanco Animal Health Incorporated has revealed plans for a 25,000-sq. ft expansion of its biologics manufacturing site in Kansas, United States. This anticipated USD 130 million investment, set to be completed by 2026, aims to enhance the company's monoclonal antibody (mAb) platform for canine parvovirus monoclonal antibody (CPMA), leveraging the existing strong expertise at this facility.
- July 2024: Invetx Inc. introduced its agreement to be acquired by Dechra Pharmaceuticals Limited (Dechra) for up to USD 520 million on a cash-free and debt-free basis. This acquisition aims to enhance the portfolio of high-value monoclonal antibody therapeutics for companion animals.
Monoclonal Antibodies In Veterinary Health Industry Segmentation
According to the scope, monoclonal antibodies are the antibodies that are developed by the immune cells to mimic the immune responses caused by the pathogens in animal health. These antibodies are highly effective in preventing and treating cancer, autoimmune diseases, and chronic infections in animals; thus, they are highly adopted by veterinarians.
The monoclonal antibodies in veterinary health 乐鱼体育官网 is segmented by animal type, application, end user, and geography. By animal type, the 乐鱼体育官网 is segmented into dogs and other animal types. By application, the 乐鱼体育官网 is segmented into dermatology, pain, and other applications. By end user, the 乐鱼体育官网 is segmented into veterinary hospitals and other end users. By geography, the 乐鱼体育官网 is segmented into North America, Europe, Asia-Pacific, and Rest of the World. The 乐鱼体育官网 size is provided for each segment in terms of value (USD).
| By Animal Type | Dogs | ||
| Other Animal Types | |||
| By Application | Dermatology | ||
| Pain | |||
| Other Applications | |||
| By End User | Veterinary Hospitals | ||
| Other End Users | |||
| By Geography | North America | United States | |
| Canada | |||
| Mexico | |||
| Europe | Germany | ||
| United Kingdom | |||
| France | |||
| Italy | |||
| Spain | |||
| Rest of Europe | |||
| Asia-Pacific | China | ||
| Japan | |||
| India | |||
| Australia | |||
| South Korea | |||
| Rest of Asia-Pacific | |||
| Rest of the World | |||
Need A Different Region or Segment?
Customize Now
Monoclonal Antibodies In Veterinary Health 乐鱼体育官网 Research FAQs
How big is the Monoclonal Antibodies In Veterinary Health 乐鱼体育官网?
The Monoclonal Antibodies In Veterinary Health 乐鱼体育官网 size is expected to reach USD 1.17 billion in 2025 and grow at a CAGR of 16.60% to reach USD 2.51 billion by 2030.
What is the current Monoclonal Antibodies In Veterinary Health 乐鱼体育官网 size?
In 2025, the Monoclonal Antibodies In Veterinary Health 乐鱼体育官网 size is expected to reach USD 1.17 billion.
Who are the key players in Monoclonal Antibodies In Veterinary Health 乐鱼体育官网?
Merck & Co, Bayer Animal Health, Zoetis, Elanco and Boehringer Ingelheim Gmbh are the major companies operating in the Monoclonal Antibodies In Veterinary Health 乐鱼体育官网.
Which is the fastest growing region in Monoclonal Antibodies In Veterinary Health 乐鱼体育官网?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).
Which region has the biggest share in Monoclonal Antibodies In Veterinary Health 乐鱼体育官网?
In 2025, the North America accounts for the largest 乐鱼体育官网 share in Monoclonal Antibodies In Veterinary Health 乐鱼体育官网.
What years does this Monoclonal Antibodies In Veterinary Health 乐鱼体育官网 cover, and what was the 乐鱼体育官网 size in 2024?
In 2024, the Monoclonal Antibodies In Veterinary Health 乐鱼体育官网 size was estimated at USD 0.98 billion. The report covers the Monoclonal Antibodies In Veterinary Health 乐鱼体育官网 historical 乐鱼体育官网 size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Monoclonal Antibodies In Veterinary Health 乐鱼体育官网 size for years: 2025, 2026, 2027, 2028, 2029 and 2030.
Monoclonal Antibodies In Veterinary Health Industry Report
Statistics for the 2025 Monoclonal Antibodies In Veterinary Health 乐鱼体育官网 share, size and revenue growth rate, created by Mordor Intelligence鈩� Industry Reports. Monoclonal Antibodies In Veterinary Health analysis includes a 乐鱼体育官网 forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.
